NASDAQ:AEZS - AEterna Zentaris Stock Price, News & Analysis

$2.08
+0.01 (+0.48 %)
(As of 08/23/2019 06:00 AM ET)
Today's Range
$2.06
Now: $2.08
$2.10
50-Day Range
$2.07
MA: $2.47
$2.90
52-Week Range
$1.29
Now: $2.08
$5.57
Volume18,534 shs
Average Volume73,113 shs
Market Capitalization$34.20 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AEZS
CUSIPN/A
Phone843-900-3223

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.90 million
Cash Flow$0.2178 per share
Book Value($0.18) per share

Profitability

Net Income$4.19 million
Net Margins-536.79%

Miscellaneous

EmployeesN/A
Market Cap$34.20 million
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive AEZS News and Ratings via Email

Sign-up to receive the latest news and ratings for AEZS and its competitors with MarketBeat's FREE daily newsletter.


AEterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions

What is AEterna Zentaris' stock symbol?

AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."

How were AEterna Zentaris' earnings last quarter?

AEterna Zentaris Inc. (NASDAQ:AEZS) posted its quarterly earnings data on Tuesday, August, 13th. The biopharmaceutical company reported $0.01 EPS for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.15. The biopharmaceutical company earned $0.19 million during the quarter, compared to the consensus estimate of $0.20 million. AEterna Zentaris had a negative net margin of 536.79% and a negative return on equity of 1,428.66%. View AEterna Zentaris' Earnings History.

When is AEterna Zentaris' next earnings date?

AEterna Zentaris is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for AEterna Zentaris.

What price target have analysts set for AEZS?

2 Wall Street analysts have issued 12-month target prices for AEterna Zentaris' stock. Their forecasts range from $2.00 to $3.00. On average, they expect AEterna Zentaris' stock price to reach $2.50 in the next year. This suggests a possible upside of 20.2% from the stock's current price. View Analyst Price Targets for AEterna Zentaris.

What is the consensus analysts' recommendation for AEterna Zentaris?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AEterna Zentaris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AEterna Zentaris.

What are Wall Street analysts saying about AEterna Zentaris stock?

Here are some recent quotes from research analysts about AEterna Zentaris stock:
  • 1. HC Wainwright analysts commented, "We maintain our Buy rating of AEZS and our 12-month price target of $5.50 per share. We derive our price target using a risk- adjusted net present value analysis of potential US and EU royalties, discounted at 18%, to reach a total rNPV of $66M for the royalty streams." (8/15/2019)
  • 2. According to Zacks Investment Research, "AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. " (3/22/2019)

Has AEterna Zentaris been receiving favorable news coverage?

News articles about AEZS stock have trended positive on Friday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AEterna Zentaris earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for AEterna Zentaris.

Are investors shorting AEterna Zentaris?

AEterna Zentaris saw a decrease in short interest during the month of July. As of July 31st, there was short interest totalling 401,700 shares, a decrease of 6.5% from the June 30th total of 429,400 shares. Based on an average daily trading volume, of 112,200 shares, the short-interest ratio is currently 3.6 days. Currently, 4.1% of the company's stock are sold short. View AEterna Zentaris' Current Options Chain.

Who are some of AEterna Zentaris' key competitors?

What other stocks do shareholders of AEterna Zentaris own?

Who are AEterna Zentaris' key executives?

AEterna Zentaris' management team includes the folowing people:
  • Mr. Michael V. Ward, Pres & CEO (Age 62)
  • Ms. Leslie Auld, Sr. VP & CFO
  • Mr. Brian Garrison, Sr. VP of Global Corp. Operations & Corp. Devel.
  • Dr. Nicola Ammer, Chief Medical Officer & VP of Clinical Devel.
  • Mr. Olaf Althaus, GM & MD

Who are AEterna Zentaris' major shareholders?

AEterna Zentaris' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Morgan Stanley (4.18%), BlackRock Inc. (0.28%) and Creative Planning (0.06%).

Which major investors are selling AEterna Zentaris stock?

AEZS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley.

Which major investors are buying AEterna Zentaris stock?

AEZS stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc. and Creative Planning.

How do I buy shares of AEterna Zentaris?

Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AEterna Zentaris' stock price today?

One share of AEZS stock can currently be purchased for approximately $2.08.

How big of a company is AEterna Zentaris?

AEterna Zentaris has a market capitalization of $34.20 million and generates $26.90 million in revenue each year. The biopharmaceutical company earns $4.19 million in net income (profit) each year or $0.25 on an earnings per share basis. View Additional Information About AEterna Zentaris.

What is AEterna Zentaris' official website?

The official website for AEterna Zentaris is http://www.aezsinc.com/.

How can I contact AEterna Zentaris?

AEterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The biopharmaceutical company can be reached via phone at 843-900-3223 or via email at [email protected]


MarketBeat Community Rating for AEterna Zentaris (NASDAQ AEZS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  363 (Vote Outperform)
Underperform Votes:  254 (Vote Underperform)
Total Votes:  617
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe AEZS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEZS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel